Registration is Now Open for Tribe Public’s Webinar Event "Now Is Not the Time to Monkey(pox) Around" Featuring GeoVax Lab’s CEO
21 Agosto 2024 - 3:00PM
GeoVax Lab, Inc. (Nasdaq: GOVX) ("GeoVax Labs" or the "Company"),
a biotechnology company developing immunotherapies and
vaccines against cancers and infectious diseases, today announced
that David Dodd, CEO of GeoVax Labs, will present at Tribe Public’s
Webinar Presentation and Q&A Event titled "Now Is Not the Time
to Monkey(pox) Around." The Event is scheduled to begin at
8:00am PT / 11:00am ET on Friday, August 23, 2024. To register to
join the complimentary event, please visit the Tribe Public LLC
website at MonkeyPox.TribePublic.com.
Once registered, participants may begin forwarding their
questions for the CEO to Tribe Public at research@tribepublic.com
or share their questions via the ZOOM chat feature during the
event. Tribe Public’s Managing Member, John F. Heerdink, Jr., will
host the event and relay all questions to management.
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company
developing novel vaccines for many of the world’s most threatening
infectious diseases and therapies for solid tumor cancers. The
company’s lead clinical program is GEO-CM04S1, a next-generation
COVID-19 vaccine for which GeoVax was recently awarded a
BARDA-funded contract to sponsor a 10,000-participant Phase 2b
clinical trial to evaluate the efficacy of GEO-CM04S1 versus an
approved COVID-19 vaccine. In addition, GEO-CM04S1 is currently in
three Phase 2 clinical trials, being evaluated as (1) a primary
vaccine for immunocompromised patients such as those suffering from
hematologic cancers and other patient populations for whom the
current authorized COVID-19 vaccines are insufficient, (2) a
booster vaccine in patients with chronic lymphocytic leukemia (CLL)
and (3) a more robust, durable COVID-19 booster among healthy
patients who previously received the mRNA vaccines. In oncology the
lead clinical program is evaluating a novel oncolytic solid tumor
gene-directed therapy, Gedeptin®, in a multicenter Phase 1/2
clinical trial for advanced head and neck cancers. GeoVax has a
strong IP portfolio in support of its technologies and product
candidates, holding worldwide rights for its technologies and
products. The Company has a leadership team who have driven
significant value creation across multiple life science companies
over the past several decades. For more information about the
current status of our clinical trials and other updates, visit our
website: www.geovax.com.
About Tribe Public LLC
Tribe Public LLC is a San Francisco, CA based organization that
hosts complimentary worldwide webinar & meeting events in the
U.S. Tribe’s complimentary events focus on issues that the Tribe
members care about with an emphasis on hosting management teams
from publicly traded companies from all sectors & financial
organizations that are seeking to increase awareness of their
products, progress and plans. Tribe members primarily include
Family Offices, Portfolio Managers, Registered Investment Advisors,
Accredited Investors, Sell Side Analysts, and members of media.
Tribe Members are encouraged to express their interest in speakers
they care about and want to learn from at the Tribe Public website
via the Tribe’s FREE “Wish List” process. Visit Tribe Public’s
Website to learn more: https://tribepublic.com/
Company Contact: |
|
Investor Relations Contact: |
|
Media Contact: |
info@geovax.com |
|
austin.murtagh@precisionaq.com |
|
sr@roberts-communications.com |
678-384-7220 |
|
212-698-8696 |
|
202-779-0929 |
|
|
|
|
|
Grafico Azioni GeoVax Labs (NASDAQ:GOVX)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni GeoVax Labs (NASDAQ:GOVX)
Storico
Da Dic 2023 a Dic 2024